Surgical Science

Volume 2, Issue 6 (August 2011)

ISSN Print: 2157-9407   ISSN Online: 2157-9415

Google-based Impact Factor: 0.10  Citations  h5-index & Ranking

Effects of Surgery and Palliative Chemotherapy in the Treatment of Colorectal Liver Metastasis

HTML  Download Download as PDF (Size: 219KB)  PP. 312-317  
DOI: 10.4236/ss.2011.26066    5,309 Downloads   8,408 Views  Citations

Affiliation(s)

.

ABSTRACT

Purpose: 1) To compare the survival of patients with colorectal liver metastases who underwent resection as the primary treatment against patients who had chemotherapy as the primary treatment. 2) To compare the survival in patients with recurrent inoperable liver metastases (after resection) treated with Oxaliplatin or Irinotecan against those patients with inoperable recurrence who were treated with 5-FU. Patients and Methods: 538 patients with colorectal liver metastases were referred to our unit between November 1997 and May 2005; 247 underwent liver resection and 291 had palliative chemotherapy. Results: Only 7.8% of non-operated patients survived for 5 years compared to 31.5% of the liver resection group. After surgery, 191 patients developed inoperable recurrent disease. These patients were treated with chemotherapy; Ox/Ir patients had a 3 year survival of 55% compared to 32% of those who received 5-FU. Our data shows that in patients who relapse after liver surgery, chemotherapy with Oxaliplatin or Irinotecan confers a significant survival benefit.

Share and Cite:

N. Bird, R. Bird and A. Majeed, "Effects of Surgery and Palliative Chemotherapy in the Treatment of Colorectal Liver Metastasis," Surgical Science, Vol. 2 No. 6, 2011, pp. 312-317. doi: 10.4236/ss.2011.26066.

Cited by

[1] Liver regeneration and liver metastasis
2020
[2] Counting the cost of cancer surgery for advanced and metastatic disease
British Journal of Surgery.Wiley Online Library, 2012

Copyright © 2024 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.